Abstract 348P
Background
Effective interventions to improve prognosis in non-small-cell lung cancer (NSCLC) are urgently needed. We assessed the effect of the early integration of interdisciplinary palliative care for patients with NSCLC on the nutritional status, quality of life (QoL), psychological state and cancer pain.
Methods
In this randomised controlled trial, 120 newly diagnosed NSCLC patients were enrolled and randomly assigned (1:1) to the combined early palliative care (CEPC) group integrated with standard oncologic care or standard oncological care (SC) group. QoL and psychological state were assessed at baseline and at 24 weeks by Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9), respectively. Cancer nutritional and pain status were assessed with the use of the Patient-Generated Subjective Global Assessment (PG-SGA) and Numerical Rating Scale (NRS), respectively. The primary outcome was the change in the quality of life, psychological state and nutritional status at 24 weeks. Analysis was by intention to treat.
Results
120 patients were enrolled: 60 in CEPC group (38 completed) and 60 in the SC group(32 completed). Patients in CEPC group had a better nutritional status [severe malnutrition: 11.67% (7/60); mild or moderate malnutrition: 61.67% (37/60); no malnutrition: 26.67% (16/60)] than SC group[severe malnutrition: 36.67% (22/60); mild or moderate malnutrition: 55.0% (33/60); no malnutrition: 8.3% (5/60)] (P=0.001). Furthermore, CEPC group had a better QoL than SC group (P<0.05). In addition, fewer patients in the CEPC group than in the SC group had depressive (P=0.005) symptoms. There was no significant difference in NRS score between CEPC group and SC group.
Conclusions
Among patients with non-small-cell lung cancer, early palliative care led to significant improvements in nutritional status, quality of life and psychological state.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
396P - Mutational profiling by next generation sequencing in patients with metastatic non-small cell lung carcinoma
Presenter: Hitesh Deka
Session: Poster viewing 05.
397TiP - Phase III LUNAR study: Tumor treating fields (TTFields) with standard of care for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure
Presenter: Li Zhang
Session: Poster viewing 05.
398TiP - MARIPOSA-2: Randomized phase III study of amivantamab + lazertinib + chemotherapy vs chemotherapy alone in EGFR-mutant NSCLC after osimertinib failure
Presenter: Jie Wang
Session: Poster viewing 05.